UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology, a biotechnology firm focused on developing therapeutics to combat aging, has granted a stock-based award of 30,000 shares to a new employee from June 14 to June 28, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UNITY Biotechnology, a biotechnology firm focused on developing therapeutics to combat aging, has granted a stock-based award of 30,000 shares to a new employee from June 14 to June 28, 2022. This grant, which includes options to purchase the same amount of stock, is made under the UNITY 2020 Employment Inducement Incentive Plan. This plan is designed to attract new talent, complying with Nasdaq Rule 5635(c)(4). UNITY aims to create medicines that target age-related diseases, particularly in ophthalmology and neurology.
Positive
- Grant of 30,000 stock-based awards to attract new talent.
Negative
- None.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was +0.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from June 14, 2022, through June 28, 2022, the Compensation Committee of the Board of Directors (the “Board”) granted a new employee a stock-based award covering an aggregate of 30,000 shares of UNITY common stock, including options to purchase an aggregate of 30,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Media Contact:
Canale Communications
Jason Spark
jason.spark@canalecomm.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.